Bays Harold, Jones Peter H
L-MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA.
Vasc Health Risk Manag. 2007;3(5):733-42.
Colesevelam HCl is a bile acid sequestrant (BAS) which has been specifically designed with a unique structure for the purpose of improving tolerability and reducing potential drug interactions compared to older BAS, such as cholestyramine and colestipol. As a class, BAS are known to reduce cholesterol and glucose levels, and to reduce atherosclerotic coronary heart disease (CHD) risk as monotherapy, and in combination with other lipid-altering drug therapies. Colesevelam HCl has specifically been shown to reduce total and low-density lipoprotein (LDL) cholesterol levels, and has been approved as a cholesterol-lowering drug since year 2000. It has also been shown to reduce glucose levels. This discussion reviews mechanisms by which BAS lower cholesterol, and potential mechanisms by which BAS lower glucose levels in patients with type 2 diabetes mellitus. Finally this paper specifically reviews colesevelam HCl's pharmacology, lipid and glucose efficacy, safety/tolerability, and clinical use.
盐酸考来维仑是一种胆汁酸螯合剂（BAS），其结构独特，旨在与诸如考来烯胺和考来替泊等较老的BAS相比，提高耐受性并减少潜在的药物相互作用。作为一类药物，BAS已知可降低胆固醇和葡萄糖水平，并作为单一疗法以及与其他降脂药物疗法联合使用时，降低动脉粥样硬化性冠心病（CHD）风险。盐酸考来维仑已被特别证明可降低总胆固醇和低密度脂蛋白（LDL）胆固醇水平，自2000年以来已被批准为降胆固醇药物。它也已被证明可降低葡萄糖水平。本讨论回顾了BAS降低胆固醇的机制，以及BAS降低2型糖尿病患者葡萄糖水平的潜在机制。最后，本文特别回顾了盐酸考来维仑的药理学、脂质和葡萄糖疗效、安全性/耐受性以及临床应用。
